At 2022 IGCS, Tiffany Sia, MD, spoke about using procedural interventions to treat patients with gynecologic malignancies who have oligoprogression on treatment with immune checkpoint inhibitors.
Caitlin Costello, MD, describes how to determine if a patient with MM is transplant-ineligible, and some factors to take into consideration when choosing a treatment regimen.
The panel explains their opinions on induction therapy approaches for high-risk and standard-risk patients with NDMM.
Drs Cheson and Park briefly review previous data from the E7438-G000-101 trial on tazemetostat in patients with wild-type or EZH2-mutant R/R FL, and then describe the findings of a more recent 2022 propensity score-matched analysis of the data that was intended to address baseline clinical differences between the two patient populations.
Drs Nooka and Pianko discuss how they measure a successful treatment response in patients with transplant-eligible multiple myeloma after induction therapy.
An oncologist muses on the potential of real-world data in evaluating the use of a quadruplet regimen for newly diagnosed transplant-eligible multiple myeloma.
In terms of tumor control, treatment with cabozantinib and atezolizumab led to an overall response rate of 19% among patients with advanced non–small cell lung cancer, according to Joel W. Neal, MD, PhD.